Literature DB >> 5069747

A new potent -glucuronidase inhibitor, D-glucaro- -lactam derived from nojirimycin.

T Niwa, T Tsuruoka, S Inoue, Y Naito, T Koeda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5069747     DOI： 10.1093/oxfordjournals.jbchem.a129889

Source DB:  PubMed          Journal:  J Biochem        ISSN： 0021-924X            Impact factor:   3.387


× No keyword cloud information.
  5 in total

1.  Alleviating cancer drug toxicity by inhibiting a bacterial enzyme.

Authors:  Bret D Wallace; Hongwei Wang; Kimberly T Lane; John E Scott; Jillian Orans; Ja Seol Koo; Madhukumar Venkatesh; Christian Jobin; Li-An Yeh; Sridhar Mani; Matthew R Redinbo
Journal:  Science       Date:  2010-11-05       Impact factor: 47.728

2.  Animal studies on the reduction of aminoglycoside-induced nephrotoxicity by D-glucaro-1,5-lactam.

Authors:  R Marre; W Müller; K Sack
Journal:  Infection       Date:  1983 May-Jun       Impact factor: 3.553

3.  A High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors.

Authors:  Syed Ahmad; Mark A Hughes; Kimberly T Lane; Matthew R Redinbo; Li-An Yeh; John E Scott
Journal:  Curr Chem Genomics       Date:  2011-04-08

4.  Inhibition of pulmonary metastases and tumor cell invasion in experimental tumors by sodium D-glucaro-delta-lactam (ND2001).

Authors:  T Tsuruoka; H Fukuyasu; M Azetaka; Y Iizuka; S Inouye; M Hosokawa; H Kobayashi
Journal:  Jpn J Cancer Res       Date:  1995-01

5.  Inhibition of tumor cell haptotaxis by sodium D-glucaro-delta-lactam (ND2001).

Authors:  T Tsuruoka; M Azetaka; Y Iizuka; K Saito; S Inouye; M Hosokawa; H Kobayashi
Journal:  Jpn J Cancer Res       Date:  1995-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.